Spyre Therapeutics Inc. (SYRE) Whale Options Tug-of-War, Max Pain & Unusual Sweeps
Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Active Strike Call vs. Put Concentration Ladder (SYRE)
Practice in Our Weekly $100,000 Prop Arena Before Risking Personal Capital
Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring SYRE)
- ✓Live walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.
SYRE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is SYRE's options max pain and whale flow sentiment?
Unusual options sweeps in SYRE show 52% bullish call premium versus 48% put premium, centered near a $97 max-pain strike.